Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Predictive value of pseudouridine in prostate cancer.

Stockert JA, Gupta A, Herzog B, Yadav SS, Tewari AK, Yadav KK.

Am J Clin Exp Urol. 2019 Aug 25;7(4):262-272. eCollection 2019.

2.

Inflammation and Prostate Cancer.

Tewari AK, Stockert JA, Yadav SS, Yadav KK, Khan I.

Adv Exp Med Biol. 2018;1095:41-65. doi: 10.1007/978-3-319-95693-0_3. Review.

PMID:
30229548
3.

Intratumor heterogeneity in prostate cancer.

Yadav SS, Stockert JA, Hackert V, Yadav KK, Tewari AK.

Urol Oncol. 2018 Aug;36(8):349-360. doi: 10.1016/j.urolonc.2018.05.008. Epub 2018 Jun 7. Review.

PMID:
29887240
4.

Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications.

Yadav SS, Li J, Stockert JA, Herzog B, O'Connor J, Garzon-Manco L, Parsons R, Tewari AK, Yadav KK.

Transl Oncol. 2017 Jun;10(3):357-366. doi: 10.1016/j.tranon.2017.01.011. Epub 2017 Mar 24.

5.

Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer.

Yadav SS, Li J, Stockert JA, O'Connor J, Herzog B, Elaiho C, Galsky MD, Tewari AK, Yadav KK.

Oncotarget. 2016 Nov 15;7(46):76181-76196. doi: 10.18632/oncotarget.12771.

6.

Identification of a small-molecule ligand that activates the neuropeptide receptor GPR171 and increases food intake.

Wardman JH, Gomes I, Bobeck EN, Stockert JA, Kapoor A, Bisignano P, Gupta A, Mezei M, Kumar S, Filizola M, Devi LA.

Sci Signal. 2016 May 31;9(430):ra55. doi: 10.1126/scisignal.aac8035.

7.

Advancements in therapeutically targeting orphan GPCRs.

Stockert JA, Devi LA.

Front Pharmacol. 2015 May 8;6:100. doi: 10.3389/fphar.2015.00100. eCollection 2015. Review.

Supplemental Content

Loading ...
Support Center